Moleculin Biotech (MBRX) Competitors $1.04 -0.01 (-0.95%) Closing price 04:00 PM EasternExtended Trading$1.04 0.00 (-0.10%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBRX vs. ALVR, ITRM, RPTX, IBIO, IMMX, NBRV, CNTB, FGEN, ICCC, and RNTXShould you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include AlloVir (ALVR), Iterum Therapeutics (ITRM), Repare Therapeutics (RPTX), iBio (IBIO), Immix Biopharma (IMMX), Nabriva Therapeutics (NBRV), Connect Biopharma (CNTB), FibroGen (FGEN), ImmuCell (ICCC), and Rein Therapeutics (RNTX). These companies are all part of the "pharmaceutical products" industry. Moleculin Biotech vs. AlloVir Iterum Therapeutics Repare Therapeutics iBio Immix Biopharma Nabriva Therapeutics Connect Biopharma FibroGen ImmuCell Rein Therapeutics Moleculin Biotech (NASDAQ:MBRX) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation, analyst recommendations and community ranking. Do analysts recommend MBRX or ALVR? Moleculin Biotech presently has a consensus price target of $17.33, suggesting a potential upside of 1,566.67%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Moleculin Biotech is more favorable than AlloVir.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in MBRX or ALVR? Moleculin Biotech received 204 more outperform votes than AlloVir when rated by MarketBeat users. However, 57.45% of users gave AlloVir an outperform vote while only 49.36% of users gave Moleculin Biotech an outperform vote. CompanyUnderperformOutperformMoleculin BiotechOutperform Votes23149.36% Underperform Votes23750.64% AlloVirOutperform Votes2757.45% Underperform Votes2042.55% Which has more risk & volatility, MBRX or ALVR? Moleculin Biotech has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Is MBRX or ALVR more profitable? AlloVir's return on equity of -71.03% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Moleculin BiotechN/A -157.44% -97.16% AlloVir N/A -71.03%-61.27% Which has higher valuation and earnings, MBRX or ALVR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoleculin BiotechN/AN/A-$29.77MN/AN/AAlloVirN/AN/A-$190.42M-$20.23-0.45 Does the media favor MBRX or ALVR? In the previous week, Moleculin Biotech had 18 more articles in the media than AlloVir. MarketBeat recorded 21 mentions for Moleculin Biotech and 3 mentions for AlloVir. Moleculin Biotech's average media sentiment score of 0.67 beat AlloVir's score of 0.43 indicating that Moleculin Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 1 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AlloVir 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in MBRX or ALVR? 15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 1.9% of Moleculin Biotech shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryMoleculin Biotech beats AlloVir on 8 of the 13 factors compared between the two stocks. Remove Ads Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBRX vs. The Competition Export to ExcelMetricMoleculin BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.29M$6.91B$5.63B$7.83BDividend YieldN/A2.73%4.57%4.00%P/E RatioN/A7.1723.3318.67Price / SalesN/A220.47388.4691.01Price / CashN/A65.6738.1634.64Price / Book0.096.396.894.23Net Income-$29.77M$142.12M$3.20B$247.15M7 Day Performance-4.59%-5.18%-3.02%-2.17%1 Month Performance-19.38%-7.49%1.63%-5.68%1 Year Performance-82.40%-8.78%9.74%-0.67% Moleculin Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBRXMoleculin Biotech2.9093 of 5 stars$1.04-1.0%$17.33+1,566.7%-81.0%$11.29MN/A0.0020Analyst UpgradeShort Interest ↓Analyst RevisionNews CoverageALVRAlloVir2.2019 of 5 stars$9.66+0.1%N/A-47.4%$48.72MN/A-0.48110Gap UpITRMIterum Therapeutics2.0394 of 5 stars$1.40+1.4%$5.00+257.1%-18.9%$48.41MN/A-1.0710Positive NewsRPTXRepare Therapeutics3.4132 of 5 stars$1.14+3.2%$4.50+296.5%-77.1%$48.25M$53.48M-0.57180Positive NewsIBIOiBio0.7717 of 5 stars$4.86-4.3%$4.30-11.5%+29.3%$47.99M$375,000.000.00100Analyst RevisionNews CoverageGap UpIMMXImmix Biopharma2.7469 of 5 stars$1.73+4.8%$7.00+304.6%-44.3%$47.59MN/A-2.049Earnings ReportNews CoveragePositive NewsNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070Analyst ForecastNews CoverageGap DownCNTBConnect Biopharma3.5914 of 5 stars$0.82-4.0%$8.00+873.2%-52.8%$45.42M$24.12M0.00110Short Interest ↓News CoveragePositive NewsGap UpFGENFibroGen4.5631 of 5 stars$0.45+1.3%$10.00+2,147.2%-87.3%$44.84M$180.02M-0.36570Positive NewsGap UpICCCImmuCell0.8025 of 5 stars$4.97-0.4%N/A-7.2%$44.29M$26.49M-9.9470Short Interest ↓Positive NewsRNTXRein TherapeuticsN/A$2.03+1.5%N/AN/A$43.98MN/A-0.659Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies ALVR Competitors ITRM Competitors RPTX Competitors IBIO Competitors IMMX Competitors NBRV Competitors CNTB Competitors FGEN Competitors ICCC Competitors RNTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBRX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredRevealed: The Chip Stock Redefining AI as We Know ItIn this urgent presentation, Wall Street's so-called "AI Oracle" unveils the name of a small American tech fir...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MBRX Stock Free MBRX Stock Alerts